MD Anderson Cancer Center at ENA 2026
Nov 18–20, 2026 Barcelona, Spain ~1.5k attendees Website
MD Anderson Cancer Center brings 16 presentations to ENA 2026 in Barcelona. Its program centres on antibody-drug conjugates and radiopharmaceuticals, alongside early clinical trials of targeted agents and AI in drug development. Highlights include phase 1 data on the WEE1 inhibitor APR-1051 and on the GLS1 inhibitor IACS-6274 combined with bevacizumab and paclitaxel in advanced ovarian cancer.
| Organization | ENA 2026 Attendance |
|---|---|
MD Anderson Cancer Center Houston, Texas | |
University of Texas cancer centre for patient care, research and early-phase clinical trials. | Session Wed Nov 18 4:15–5:45pm Talk Wed Nov 18 4:55–5:15pm Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Talk Thu Nov 19 10–10:10am Session Thu Nov 19 2–2:30pm Session Thu Nov 19 3–4:30pm Session Thu Nov 19 3–4:30pm Talk Thu Nov 19 3:20–3:40pm Talk Thu Nov 19 3:40–4pm Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Talk Fri Nov 20 3–3:10pm Poster Fri Nov 20 10:45–11:15am 1:30–3pm |
Instantly find 20 buyers from MD Anderson Cancer Center
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by EORTC, the NCI or the AACR. Submit a correction